Healthy Living Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.

Press releases published on November 9, 2026

Nov. 9, 2026

Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies

Indeterminate GlobeNewswire

Nov. 9, 2026

LifeStance Health Group Announces Launch of Secondary Public Offering

Indeterminate GlobeNewswire

Nov. 9, 2026

Home Instead Gives Ferris Bueller’s Sister the Day Off She Never Got

Indeterminate GlobeNewswire

Nov. 9, 2026

Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress

Indeterminate GlobeNewswire

Nov. 9, 2026

Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement

Indeterminate GlobeNewswire

Nov. 9, 2026

DeepLife and 3billion partner to discover small-molecule therapeutics against genetic modifier targets across multiple diseases

Indeterminate GlobeNewswire

Nov. 9, 2026

German Institute Apologizes for Nazi Psychiatry, Vindicates Citizens Commission on Human Rights International

Indeterminate GlobeNewswire

Nov. 9, 2026

Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting

Indeterminate GlobeNewswire

Nov. 9, 2026

Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan

Indeterminate GlobeNewswire

Nov. 9, 2026

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

Indeterminate GlobeNewswire

Nov. 9, 2026

Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer  

Indeterminate GlobeNewswire

Nov. 9, 2026

Epitopea annonce l'administration de la première dose à une patiente dans le cadre de l'essai clinique OVACT de phase 1/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire séreux de haut grade avancé  

Indeterminate GlobeNewswire

Nov. 9, 2026

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026

Indeterminate GlobeNewswire

Nov. 9, 2026

iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells

Indeterminate GlobeNewswire

Nov. 9, 2026

Truveta launches care insights solution to inform pre-launch planning, then follow treatments after approval and into clinical practice

Indeterminate GlobeNewswire

Nov. 9, 2026

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

Indeterminate GlobeNewswire

Nov. 9, 2026

GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027

Indeterminate GlobeNewswire

Nov. 9, 2026

GENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027

Indeterminate GlobeNewswire

Nov. 9, 2026

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

Indeterminate GlobeNewswire

Nov. 9, 2026

Valneva annonce des résultats positifs de phase 2 pour son candidat vaccin tétravalent contre la shigellose S4V2

Indeterminate GlobeNewswire